Ceramedix Awarded Up to $4.5 Million NIAID Contract to Advance Lead GI-ARS Therapeutic Toward IND Submission

GI-ARS TherapeuticPositive

AI Analysis

Summary

Ceramedix received a multi-year contract of up to $4.5 million from NIAID's Radiation and Nuclear Countermeasures Program to advance its lead GI-ARS therapeutic candidate toward IND submission.

Outcome Details

Contract awarded for advancement toward IND submission

Importance:5/10

Sentiment:

0.60

government fundingNIAID contractIND submissionGI-ARSrare diseasebiodefense

Related Companies

$NHPAP

Read the original article

Published by PR Newswire Biotech on August 11, 2026 12:31 PM

Read Original